Pemetrexed-induced scleroderma-like changes in the lower legs;Sclérose cutanée des deux membres inférieurs sous pemetrexed

Annales de Dermatologie et de Venereologie

Volumn 142, Issue 2, 2015, Pages 115-120

  Corbaux, C ^a   Marie, J ^b   Meraud, J P ^b   Lacroix, S ^b   Delhoume, J Y ^b   Jouary, T ^c   Madoui, S ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b centre hospitalier de Périgueux   (France)

^c CENTRE HOSPITALIER DE PAU   (France)

Author keywords

Anti folates; Cutaneous toxicity; Erysipelas like; Pemetrexed; Scleroderma

Indexed keywords

CISPLATIN; CLOXACILLIN; PEMETREXED; ANTINEOPLASTIC AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CELLULITIS; CLINICAL FEATURE; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHEMA; FEMALE; HUMAN; LOWER LEG; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MALE; NON SMALL CELL LUNG CANCER; SCLERODERMA; SKIN BRUISING; CHEMICALLY INDUCED; DRUG ERUPTIONS; LEG; LOCALIZED SCLERODERMA;

AGED; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; LEG; MALE; PEMETREXED; SCLERODERMA, LOCALIZED;

EID: 84922404555     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2014.11.011     Document Type: Article

References (24)

1. Hazarika M, White Jr RM, Booth BP, Wang YC, Ham DY, LiangCY, et al. Pemetrexed in malignant pleural mesothelioma. ClinCancer Res 2005;11:982-92.
2. Zalcman G, Bergot E, Lechapt E. Pemetrexed rechallenge inpleural malignant mesothelioma: an option for a subset ofpatients initially treated with pemetrexed-platinum doubletsin the first-line setting? Lung Cancer 2011;72:1-2.
3. Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L. Malignantpleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 2009;14:423-37.
4. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary:pemetrexed maintenance therapy of advanced/metastaticnon-squamous, non-small cell lung cancer (NSCLC). Oncologist2010;15:1352-8.
5. Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, SaccoPC, et al. Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 2011;10:311-7.
6. Payne AS, James WD, Weiss RB. Dermatologic toxicity of che-motherapeutic agents. Semin Oncol 2006;33:86-97.
7. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F,von Pawel J, et al. Randomized phase III trial of pemetrexedversus docetaxel in patients with non-small cell lung cancerpreviously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
8. Merklen-Djafri C, Imbert E, Courouge-Dorcier D, Schott R,Méraud JP, Muller C, et al. Pemetrexed-induced skin sclerosis. Clin Oncol 2012;24:452-3.
9. Vitiello M, Romanelli P, Kerdel FA. Painful generalized erythe-matous patches: a severe and unusual cutaneous reaction topemetrexed. J Am Acad Dermatol 2011;65:243-4.
10. Eguia B, Ruppert AM, Fillon J, Lavolé A, Gounant V, Epaud C,et al. Skin toxicities compromise prolonged pemetrexed treat-ment. J Thorac Oncol 2011;6:2083-9.
11. Salle De Chou C, Halabi-Tawil M, Bagot M, Guibal F. Unenouvelle toxicité à ne pas méconnaître : la sclérose cutanéealgique induite par le pemetrexed (Alimta). Ann DermatolVenereol 2012;139S3:B287-8.
12. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDAdrug approval summary: pemetrexed for injection (Alimta)for the treatment of non-small cell lung cancer. Oncologist2005;10:363-8.
13. Piérard-Franchimont C, Quatresooz P, Reginster MA, Piérard GE. Revisiting cutaneous adverse reactions to pemetrexed. OncolLett 2011;2:769-72.
14. Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C, Richard MA, et al. Severe cutaneous toxicity afterpemetrexed as a second line treatment for a refractory non-small cell lung cancer. Rev Mal Respir 2007;24:635-8.
15. Barlési F, Tummino C, Tasei AM, Astoul P. Unsuccessful rechal-lenge with pemetrexed after a previous radiation recalldermatitis. Lung Cancer 2006;54:423-5.
16. Schallier D, Decoster L, Fontaine C, De Grève J. Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res 2010;30:5185-8.
17. Frouin E, Sebille G, Freudenberger S, Menecier B, Quoix E, Cri-bier B, et al. Asteatotic eczema (''eczema craquelé'') withhistopathological interface dermatitis: a new cutaneous reac-tion following pemetrexed. Br J Dermatol 2012;166:1359-60.
18. Brandes JC, Grossman SA, Ahmad H. Alteration of pemetrexedexcretion in the presence of acute renal failure and effusions:presentation of a case and review of the litterature. CancerInvest 2006;24:283-7.
19. Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R,Paoletti P, et al. Pemetrexed safety and dosing strategy. SeminOncol 2002;29:24-9 http://www. ncbi. nlm. nih. gov/pubmed?term=Bunn%20PA%20Jr%5BAuthor%5D&cauthor=true&cauthoruid=12571807
20. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, AcklandSP. Phase II trial of pemetrexed disodium in chemotherapy-naïve patients with advanced non-small cell lung cancer. AnnOncol 2002;13:737-41.
21. Kuku I, Kaya E, Sevinc A, Aydogdu I. Gemcitabine-induced ery-sipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol 2002;16:271-2.
22. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004;51:S73-6.
23. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and theskin: an update. J Am Acad Dermatol 2008;58:545-70.
24. Itoh M, Yanaba K, Kobayashi T, Nakagawa H. Taxane-inducedscleroderma. Br J Dermatol 2007;156:363-7.